These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
32. Platelet receptors as therapeutic targets: Past, present and future. Jamasbi J; Ayabe K; Goto S; Nieswandt B; Peter K; Siess W Thromb Haemost; 2017 Jun; 117(7):1249-1257. PubMed ID: 28597906 [TBL] [Abstract][Full Text] [Related]
33. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
34. [Current antiplatelet agents, new inhibitors and therapeutic targets]. El Alaoui MZ; Guy A; Khalki L; Limami Y; Benomar A; Zaid N; Cherrah Y; Mekhfi H; Cadi R; Zaid Y Med Sci (Paris); 2020 Apr; 36(4):348-357. PubMed ID: 32356711 [TBL] [Abstract][Full Text] [Related]
35. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms. Shanker J; Gasparyan AY; Kitas GD; Kakkar VV Curr Vasc Pharmacol; 2011 Jul; 9(4):479-89. PubMed ID: 21314637 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of P2Y12 inhibitors according to diabetes, age, gender, body mass index and body weight: systematic review and meta-analyses of randomized clinical trials. Zaccardi F; Pitocco D; Willeit P; Laukkanen JA Atherosclerosis; 2015 Jun; 240(2):439-45. PubMed ID: 25897998 [TBL] [Abstract][Full Text] [Related]
37. Evolving role of platelet function testing in coronary artery interventions. Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653 [TBL] [Abstract][Full Text] [Related]
38. Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects. Marcone S; Dervin F; Fitzgerald DJ J Thromb Haemost; 2015 Jun; 13 Suppl 1():S323-31. PubMed ID: 26149042 [TBL] [Abstract][Full Text] [Related]
39. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Vandvik PO; Lincoff AM; Gore JM; Gutterman DD; Sonnenberg FA; Alonso-Coello P; Akl EA; Lansberg MG; Guyatt GH; Spencer FA Chest; 2012 Feb; 141(2 Suppl):e637S-e668S. PubMed ID: 22315274 [TBL] [Abstract][Full Text] [Related]
40. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]